IGF-1 DES 1mg

4.9 stars

$55.00

Purchase this product now and earn 55 Points!
Category:

Size Options: 1mg Composition: Fragment 176-191 Form: Lyophilized Powder Purity: >99% Product Code: P-FRAG176-191

Enjoy Complimentary Shipping on Orders Over $200

Receive a Free 30ml Bac Water with Orders Over $200

Discounts Available for Larger Quantities

Description

IGF-1 DES 1mg

Insulin-like growth factor-1, commonly known as IGF-1, is an endogenous hormone peptide renowned for its involvement in numerous anabolic bodily functions. Within the realm of research, various forms of IGF-1 have been naturally occurring or artificially developed, demonstrating comparable or even superior potency to IGF-1 itself. One such analog of IGF-1 is IGF-1 DES.

IGF-1 DES was meticulously designed to replicate the structural composition of IGF-1 while strategically truncating the three amino acids typically found at the N-terminus. Researchers speculate that this specific omission of the tripeptide Gly-Pro-Glu renders IGF-1 DES potentially up to 10 times more potent than the stimulation IGF-1 can offer. Interestingly, the absence of this tripeptide may also reduce the affinity of IGF-1 DES for IGF-1 binding receptors, possibly resulting in heightened cell proliferation and tissue differentiation.

Overview

Studies have indicated that IGF-1 DES operates through distinct pathways. It is speculated that it may potentially trigger CA1 fEPSPs (Excitatory Postsynaptic Potential). This mechanism involves the influx of positively charged ions into the cell, leading to the generation of excitatory post-synaptic potentials. This effect may be linked to the opening of various ion channels. Notably, experiments involving the application of IGF-1 DES for 15 minutes have demonstrated a notable 40% increase in the slope of CA1 fEPSPs, suggesting that the peptide could influence cellular function by interacting with and stimulating ion channels.

Further experimental investigations have proposed that IGF-1 DES might enhance excitatory synaptic transmission, primarily mediated through the PI3K pathway. In an effort to explore the potential for excitatory transmission in the CA1 region, researchers conducted an experiment. Brain cells were exposed to IGF-1 DES, either alone or in conjunction with tyrosine inhibitor or PI3K inhibitor compounds. Both tyrosine kinase and PI3K are recognized in the scientific community as enzymatic players involved in cell growth, differentiation, and proliferation. Findings from the study indicated that tyrosine kinase inhibitors did not appear to impede the functioning of IGF-1 DES. In contrast, PI3K inhibitor compounds were observed to significantly diminish the fEPSP slope.

Research and Clinical Studies

IGF-1 DES and Neurological Effects

A study investigated the impact of IGF-1 and its analogs on SHANK3-depleted mice over a two-week period. Daily administration of the peptide for this duration resulted in what researchers described as a reversal of several neurological deficits associated with SHANK3 deficiency, including improvements in motor signaling and performance.

In a separate study, mice induced with Rett Syndrome, a condition linked to neurological impairments, were treated with IGF-1 and its analogs, including IGF-1 DES. The analogs were found to enhance synaptic development and mitigate phenotype defects. Researchers in both studies suggested that IGF-1 and its analogs hold promise for inhibiting the development and progression of neurological deterioration.

IGF-1 DES and Autism Mouse Models

Autism spectrum disorder, characterized by impaired brain development, has been associated with deficits in synaptic development, sharing similarities with conditions like tuberous sclerosis. An experiment involving mouse models of autism treated with IGF-II and its analogs, including IGF-1 DES, showed promising results. Within just five days, the peptide appeared to enhance social interaction, reduce compulsive behavior, and significantly improve cognitive functioning in the mice.

IGF-1 DES and Cognitive Function

Research has indicated that IGF-1, a peptide hormone, plays a crucial role in growth and development. While most peptides are produced by the liver, certain short peptide isoforms, like IGF-1 DES, are believed to have neuroprotective potential that extends beyond conventional IGF-1 receptor actions. These short isoforms, known for their ability to easily cross the blood-brain barrier and stability, were the focus of a study involving the hippocampal brain cells of young rats. Administration of IGF-1 DES reportedly led to a 40% increase in excitatory synaptic responses, primarily through AMPA receptors, potentially enhancing cognitive function. Further research is required to confirm this hypothesis.

IGF-1 DES and Immune Function

A study aimed to assess the impact of IGF-1 isoforms, including IGF-1 DES and Long R3 IGF-1, on immune function, particularly on mononuclear and neutrophil cells. Cells were preincubated with a standard agent (no IGF-1), IGF-1 DES, and Long R3 IGF-1. The results indicated a notable increase in hydrogen peroxide release from these cells, with percentages of 65%, 64%, and 32%, respectively.

IGF-1 DES and Cancer Cells

Cancer cells often remain undifferentiated or exist in early stages of differentiation, posing challenges for isolation and eradication. One approach to inhibit tumor development involves inducing differentiation in these cancer cells. Research findings suggest that when IGF-1 DES is introduced in nanomolar amounts to carcinogenic HT29-D4 cells, it may promote their differentiation. Additionally, early exposure to IGF-1 DES may moderately inhibit the proliferation of HT29-D4 cells. This study suggests that IGF-1 DES could hold potential for differentiating certain types of cancer cells, specifically colon carcinoma HT29-D4 cells.

CAS Number
PubChem CID
Molecular Weight
Molecular Formula
Synonyms
Storage (Lyophilized) At 39 Fahrenheit: 2 years At -4 Fahrenheit: 3 years

IGF-1 DES 1mg

Insulin-like growth factor-1, commonly known as IGF-1, is an endogenous hormone peptide renowned for its involvement in numerous anabolic bodily functions. Within the realm of research, various forms of IGF-1 have been naturally occurring or artificially developed, demonstrating comparable or even superior potency to IGF-1 itself. One such analog of IGF-1 is IGF-1 DES.

IGF-1 DES was meticulously designed to replicate the structural composition of IGF-1 while strategically truncating the three amino acids typically found at the N-terminus. Researchers speculate that this specific omission of the tripeptide Gly-Pro-Glu renders IGF-1 DES potentially up to 10 times more potent than the stimulation IGF-1 can offer. Interestingly, the absence of this tripeptide may also reduce the affinity of IGF-1 DES for IGF-1 binding receptors, possibly resulting in heightened cell proliferation and tissue differentiation.

Overview

Studies have indicated that IGF-1 DES operates through distinct pathways. It is speculated that it may potentially trigger CA1 fEPSPs (Excitatory Postsynaptic Potential). This mechanism involves the influx of positively charged ions into the cell, leading to the generation of excitatory post-synaptic potentials. This effect may be linked to the opening of various ion channels. Notably, experiments involving the application of IGF-1 DES for 15 minutes have demonstrated a notable 40% increase in the slope of CA1 fEPSPs, suggesting that the peptide could influence cellular function by interacting with and stimulating ion channels.

Further experimental investigations have proposed that IGF-1 DES might enhance excitatory synaptic transmission, primarily mediated through the PI3K pathway. In an effort to explore the potential for excitatory transmission in the CA1 region, researchers conducted an experiment. Brain cells were exposed to IGF-1 DES, either alone or in conjunction with tyrosine inhibitor or PI3K inhibitor compounds. Both tyrosine kinase and PI3K are recognized in the scientific community as enzymatic players involved in cell growth, differentiation, and proliferation. Findings from the study indicated that tyrosine kinase inhibitors did not appear to impede the functioning of IGF-1 DES. In contrast, PI3K inhibitor compounds were observed to significantly diminish the fEPSP slope.

Research and Clinical Studies

IGF-1 DES and Neurological Effects

A study investigated the impact of IGF-1 and its analogs on SHANK3-depleted mice over a two-week period. Daily administration of the peptide for this duration resulted in what researchers described as a reversal of several neurological deficits associated with SHANK3 deficiency, including improvements in motor signaling and performance.

In a separate study, mice induced with Rett Syndrome, a condition linked to neurological impairments, were treated with IGF-1 and its analogs, including IGF-1 DES. The analogs were found to enhance synaptic development and mitigate phenotype defects. Researchers in both studies suggested that IGF-1 and its analogs hold promise for inhibiting the development and progression of neurological deterioration.

IGF-1 DES and Autism Mouse Models

Autism spectrum disorder, characterized by impaired brain development, has been associated with deficits in synaptic development, sharing similarities with conditions like tuberous sclerosis. An experiment involving mouse models of autism treated with IGF-II and its analogs, including IGF-1 DES, showed promising results. Within just five days, the peptide appeared to enhance social interaction, reduce compulsive behavior, and significantly improve cognitive functioning in the mice.

IGF-1 DES and Cognitive Function

Research has indicated that IGF-1, a peptide hormone, plays a crucial role in growth and development. While most peptides are produced by the liver, certain short peptide isoforms, like IGF-1 DES, are believed to have neuroprotective potential that extends beyond conventional IGF-1 receptor actions. These short isoforms, known for their ability to easily cross the blood-brain barrier and stability, were the focus of a study involving the hippocampal brain cells of young rats. Administration of IGF-1 DES reportedly led to a 40% increase in excitatory synaptic responses, primarily through AMPA receptors, potentially enhancing cognitive function. Further research is required to confirm this hypothesis.

IGF-1 DES and Immune Function

A study aimed to assess the impact of IGF-1 isoforms, including IGF-1 DES and Long R3 IGF-1, on immune function, particularly on mononuclear and neutrophil cells. Cells were preincubated with a standard agent (no IGF-1), IGF-1 DES, and Long R3 IGF-1. The results indicated a notable increase in hydrogen peroxide release from these cells, with percentages of 65%, 64%, and 32%, respectively.

IGF-1 DES and Cancer Cells

Cancer cells often remain undifferentiated or exist in early stages of differentiation, posing challenges for isolation and eradication. One approach to inhibit tumor development involves inducing differentiation in these cancer cells. Research findings suggest that when IGF-1 DES is introduced in nanomolar amounts to carcinogenic HT29-D4 cells, it may promote their differentiation. Additionally, early exposure to IGF-1 DES may moderately inhibit the proliferation of HT29-D4 cells. This study suggests that IGF-1 DES could hold potential for differentiating certain types of cancer cells, specifically colon carcinoma HT29-D4 cells.

CAS Number 
PubChem CID 
Molecular Weight 
Molecular Formula 
Synonyms 
Storage (Lyophilized)

At 39 Fahrenheit: 2 years

At -4 Fahrenheit: 3 years

Related products